首页> 生物试剂> 抗体和免疫分析> ELISA> Ontamalimab ELISA Kit,96T,DC589018-96T,Abinscience

Ontamalimab ELISA Kit,96T,DC589018-96T,Abinscience

销售价: ¥ 6756.00 / 件
在线询价
优    惠: 请询价
订货号 0BC4879
品牌型号 Abinscience DC589018-96T
库存 有库存
最小订货量 1件
联系我们
  • 400-920-3909
AbinscienceELISA其它型号产品
  • 商品介绍
  • 规格参数
  • 包装参数
技术参数 Specifications
Stability and StorageThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection methodColorimetric
Sample typePlasma, Serum
Assay typeQuantitative
Sensitivity0.156 μg/ml
Range0.31-5 μg/mL
Recovery80-120%
BackgroundOntamalimab (SHP647) is a fully human, immunoglobulin G2 , antihuman mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody being developed for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). A population pharmacokinetic/pharmacodynamic (PK/PD) analysis was conducted using clinical phase 2 study data to evaluate the PK and PD of ontamalimab following subcutaneous administrations of 7.5, 22.5, 75, and 225 mg every 4 weeks in patients with moderate to severe UC or CD. A total of 440 patients with UC (n = 249; 56.6%) or CD (n = 191; 43.4%) were included in the analysis. A 2-compartment model with parallel linear and nonlinear elimination adequately characterized concentration-time profiles of ontamalimab. The apparent clearance and volume of distribution were 0.0127 L/h (0.305 L/day) and 6.53 L, respectively. Apparent clearance and volume of distribution were mainly dependent on baseline albumin and body weight, respectively. No differences in the PK properties of ontamalimab were observed between patients with UC or CD. The presence of antidrug antibodies did not impact the PK of ontamalimab. Nonlinear elimination occurred at very low concentrations and was unlikely to contribute to the elimination half-life under steady-state conditions. A linear PK/PD model described the relationship between ontamalimab and free MAdCAM-1. Minimum concentrations of ontamalimab at steady state following 75 mg every 4 weeks were associated with >95% suppression of circulating free MAdCAM-1. The PK/PD properties characterized support phase 3 testing in UC and CD.
Alternative NamesPF-00547659, PF-547659, SHP647, CAS: 2098790-40-8
Shipping2-8 ℃
SpecificationsOntamalimab
NoteFor Research Use Only.
长度(mm)
宽度(mm)
高度(mm)
重量(kg)
猜你喜欢

在线
客服

在线客服服务时间:09:00-18:00

客服
热线

400-920-3909
客服服务热线 周一至周五(09:00-18:00)

微信
咨询

微信小程序 7X24小时在线咨询